|Principal Investigator/ Physician||Moh’d Khushman, MD|
|Sponsor||Alliance for Clinical Trials in Oncology|
|Contact Email||MCI Clinical Trials|
Protocol Title: "A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiationversus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)."
Inclusion Criteria: Diagnosis of rectal adenocarcinoma, the standard treatment recommendation in the absence of a clinical trial would be combined modality neoadjuvant chemoradiation followed by curative intent surgical resection.
Exclusion Criteria: Clinical T4 tumors, Evidence that the tumor is adherent to or invading the mesorectal fascia on imaging studies such that the surgeon would not be able to perform an RO resection (one with negative margins). Chemotherapy within 5 years prior to registration, Exceptions are colonic polyps, non-melanoma skin cancer or carcinoma-in-situ of the cervix
Clinical Trails.Gov Link: https://clinicaltrials.gov/ct2/show/NCT01515787?term=n1048&rank=1
© 2018 USA Health System